4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics announced that its compensation committee granted 141,100 Restricted Stock Units (RSUs) to 14 new non-executive employees on May 12, 2026. These RSUs were issued under the Company's 2025 Employment Inducement Award Plan, as amended, in accordance with Nasdaq Global Market Rule 5635(c)(4) to attract new talent.

4D Molecular Therapeutics reported a net loss of $68.8 million for the first quarter of 2026, a significant increase from $48.0 million in the same period last year, primarily driven by a substantial rise in research and development expenses. Collaboration and license revenue saw a notable increase to $3.0 million, largely due to the Otsuka Agreement. The company ended the quarter with $72.5 million in cash and cash equivalents, and expects to continue incurring operating losses and negative cash flows, necessitating additional funding.

4D Molecular Therapeutics reported a net loss of $68.8 million for Q1 2026, compared to $48.0 million in Q1 2025, with R&D expenses increasing to $65.0 million due to Phase 3 trials. The company announced significant operational progress, including the completion of enrollment and randomization for its 4D-150 4FRONT-1 wet AMD Phase 3 trial, with topline data expected in H1 2027. Cash, cash equivalents, and marketable securities stood at $458 million, projected to fund operations into the second half of 2028.

4D Molecular Therapeutics reported Q1 2026 financial results and significant operational progress. The company completed randomization for its 4D-150 4FRONT-1 wet AMD Phase 3 trial with 523 patients, with topline data expected in H1 2027. Additionally, 4FRONT-2 enrollment is expected to complete in H2 2026, and a global Phase 3 trial for DME is set to begin in Q3 2026. The company ended Q1 with $458 million in cash, cash equivalents, and marketable securities, projected to fund operations into the second half of 2028, despite a net loss of $68.8 million for the quarter.

4D Molecular Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 17, 2026. Stockholders will vote on the election of three Class III directors, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026, and an advisory vote on executive compensation. The Board of Directors recommends voting in favor of all proposals.